A novel noncovalent KRAS G12D inhibitor has shown significant preclinical antitumor activity in KRAS G12D tumor cells, particularly PDAC.32 ctDNA testing can also identify other targetable alterations against which there are US Food and Drug Administration–approved drugs, such as BRCA1/BRCA2, BRAF, RET, ROS1, ERBB2, NTRK alterations, and NRG1 fusions, albeit rare. This evidence concerns the gene BRAF and neoplasm.